Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and ...

JERUSALEM, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptide and protein replacement therapies, today reported ...

FDA Approval to Advance Final FemBloc® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval –– $12 Million Financing Strengthens ...

Q3 2025 Earnings Call November 13, 2025 4:30 PM ESTCompany ParticipantsMarDee Haring-Layton - Chief Accounting ...

Objective To assess the effects of behaviourally informed short message service (SMS) reminders on demand for human ...

Lantern Pharma will host a conference call and webcast to discuss third quarter 2025 financial results and business updates on Thursday, November 13, 2025 at 9:00 a.m. Eastern Time.

Q3 2025 Earnings Call Transcript November 12, 2025 BiomX Inc. beats earnings expectations. Reported EPS is $0, expectations ...

When he talks about Pat Williams, former Montana Gov. Brian Schweitzer likes to retell a story he heard from Chuck Johnson.

Operating Income Pressure -- Operating income decreased to $1.6 million from $2.6 million compared to the prior year period, ...

Trial Superiority Testing -- Statistical analysis plan allows for hierarchical testing of superiority after non-inferiority ...

The plaintiff Cup Series teams notched a win Tuesday against NASCAR. Here’s a close look at what will be discussed and disclosed at trial.

Q3 2025 Earnings Call Transcript November 3, 2025 Karyopharm Therapeutics Inc. misses on earnings expectations. Reported EPS ...